Shares of Nectar Lifesciences Ltd plummeted 20% on 8th July after hitting a day’s high of Rs 22.05. This followed the company’s announcement of a definitive business transfer agreement to sell its core business division to Ceph Lifesciences Pvt Ltd for Rs 1,270 crore on a slump sale basis.

Nectar Lifesciences has agreed to sell its core business division — which includes the manufacture, distribution, and marketing of APIs and formulations — to Ceph Lifesciences for Rs 1,270 crore. It has also signed a separate deal. This separate deal will sell its menthol business to the same buyer for Rs 20 crore.

The deal is expected to close by 20th September, 2025, subject to necessary approvals, including shareholder approval at the EGM on 4th August, 2025. However, the company clarified that the shareholding pattern will remain unchanged.

Nectar said the move is part of its strategy to streamline operations, cut debt, and boost value for shareholders. Proceeds from the sale will be used to repay debt, invest in new business areas, and reward shareholders (pending approvals). Additionally, it will support future growth plans.

Chairman Sanjiv Goyal said the company is shifting focus from mature segments to become more innovation-driven and value-focused.

At 10:25 AM, the shares of Nectar Lifesciences were trading 19.71% lower at Rs 18.57 on NSE.

Curious About Nectar Lifesciences? Ask the Analyst.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!